Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John H., Marcello, Jennifer, Herndon, James E., McLendon, Roger E., Janney, Dorothea, Friedman, Allan H., Bigner, Darell D., Friedman, Henry S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102498/
https://ncbi.nlm.nih.gov/pubmed/20443129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0217-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi